Search clinical trials for: AB1010

Total 236 results

AB Science

Completed

Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease
RAI Services Company
Celerion

Completed

CSD190103: A Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products

Tobacco Use

United States
AB Science

Completed

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Multiple Myeloma

France
RAI Services Company
Celerion

Completed

CSD190102: A Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products

Tobacco Use

United States
RAI Services Company
Celerion

Completed

CSD190101: A Study to Assess Nicotine Pharmacokinetic Parameters After Use of Two Smokeless Tobacco Products

Tobacco Use

United States
AB Science

Completed

Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

Gastro-intestinal Stromal Tumours

France
AB Science

Completed

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

Mastocytosis
AB Science

Completed

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Relapse Free

Poland, Spain, Bulgaria, France, Germany, Greece, Romania
University of California, Los Angeles

Completed

Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves

Eisenmenger Syndrome

United States
AB Science

Completed

Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis
AB Science

Completed

Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma

Asthma
AB Science

Completed

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

Asthma

Spain, Bulgaria, Czechia, France, Hungary, India
AB Science

Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects

Healthy Volunteers

United Kingdom
AB Science

Completed

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

Asthma

Malaysia, Argentina, Peru, Philippines, Ukraine
AB Science

Terminated

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

France, Singapore, United Kingdom
AB Science

Recruiting

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

Progressive Multiple Sclerosis

Spain, Sweden, France, Greece, Italy, Poland, Russian Federation, Ukraine
AB Science

Recruiting

Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Covid19 | Coronavirus Disease 2019 | SARS-CoV2 Infection

France, Russian Federation, South Africa
Zhejiang Palo Alto Pharmaceuticals, Inc.

Completed

Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects

Chronic HBV Infection

China
Kiadis Pharma

Completed

NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)

Tumors

United States, Canada
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
Allarity Therapeutics
Medical Prognosis Institute A/S; Smerud Medical Research International AS

Terminated

Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP (SMR-3184)

Relapsed/Refractory Multiple Myeloma

Denmark
Onxeo

Completed

A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors (AP1001)

Cancer

Switzerland
AB Science

Completed

Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis
AB Science

Completed

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

Czechia, France, Russian Federation, Spain, United Kingdom
AriBio Co., Ltd.

Recruiting

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Alzheimer Disease

Korea, Republic of, United States, United Kingdom
AriBio Co., Ltd.

Completed

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

Mild to Moderate Alzheimer's Disease

United States
Umecrine Mood AB

Completed

A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)

Premenstrual Dysphoric Disorder

Sweden
Zhejiang Palo Alto Pharmaceuticals, Inc.

Recruiting

Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients

Chronic HBV Infection

China
Frontier Biotechnologies Inc.

Completed

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

Chronic Low Back Pain

United States
Akeso

Completed

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

China
Eli Lilly and Company
ARMO BioSciences

Completed

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 2)

Healthy Adult Subjects

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Massachusetts General Hospital

Terminated

AT1001 for the Treatment of COVID-19 Related MIS-C

Covid19 | Multisystem Inflammatory Syndrome in Children

United States
AnaMar AB
Covance

Completed

A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis

Atopic Dermatitis

United Kingdom
AB Science

Recruiting

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Indolent Systemic Mastocytosis

France, Netherlands, Germany, United Kingdom, Russian Federation, Poland, Romania, Ukraine
Centessa Pharmaceuticals (UK) Limited
LockBody Therapeutics Ltd

Recruiting

A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

Advanced Solid Tumor

United States, France
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
Medical College of Wisconsin
National Institute on Aging (NIA)

Completed

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

APOE 4

United States
Amicus Therapeutics

Approved for marketing

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Fabry Disease

United States, Australia
Alcon Research

Completed

A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion

Symptomatic Vitreomacular Adhesion

Japan
Eli Lilly and Company
ARMO BioSciences

No longer available

An Expanded Access Program for AM0010 (Pegilodecakin)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma
Eli Lilly and Company
ARMO BioSciences

Completed

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants (Willow 3)

Healthy

United States
Eli Lilly and Company
ARMO BioSciences

Completed

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 1)

Healthy Adult Subjects

United States
Aimmune Therapeutics, Inc.

Completed

AR101 Real-World Open-Label Extension Study

Peanut Allergy

United States, Canada
AB Science

Completed

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

Spain, Bulgaria, Greece, Poland, Romania, Ukraine
Freya Biosciences ApS

Completed

FB101 Intervention in Women Screened to Have Vaginal Dysbiosis (DYSCOVER-1)

Vaginal Flora Imbalance

Ireland
Aimmune Therapeutics, Inc.

Completed

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (RAMSES)

Peanut Allergy

United States, Canada
Medexus Pharma, Inc.

Terminated

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Hemophilia B

United States, United Kingdom, India
Medtronic Heart Valves

Completed

Melody PB1016 Surveillance Study

Dysfunctional RVOT Conduits in Patients With Congenital Heart Defects

Spain, United States, Austria, Canada
AB Science

Not yet recruiting

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

Spain, France

3

Subscribe